company background image
PHM logo

Pharma Mar BME:PHM Stock Report

Last Price

€74.55

Market Cap

€1.3b

7D

-6.6%

1Y

101.5%

Updated

19 Nov, 2024

Data

Company Financials +

Pharma Mar, S.A.

BME:PHM Stock Report

Market Cap: €1.3b

PHM Stock Overview

A biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. More details

PHM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance1/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 76% below our estimate of its fair value

Earnings are forecast to grow 56.39% per year

Risk Analysis

High level of non-cash earnings

Highly volatile share price over the past 3 months compared to the Spanish market

Profit margins (0.4%) are lower than last year (8.3%)


Pharma Mar, S.A. Competitors

Grifols

BME:GRF

€6.4b

Oryzon Genomics

BME:ORY

€100.3m

Biotechnology Assets

BME:BST

€19.7m

Faes Farma

BME:FAE

€1.1b

Price History & Performance

Summary of all time highs, changes and price drops for Pharma Mar
Historical stock prices
Current Share Price€74.55
52 Week High€83.70
52 Week Low€26.16
Beta0.044
11 Month Change7.89%
3 Month Change89.98%
1 Year Change101.49%
33 Year Change32.04%
5 Year Change190.58%
Change since IPO57.28%

Recent News & Updates

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Recent updates

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

Shareholder Returns

PHMES BiotechsES Market
7D-6.6%-1.6%0.5%
1Y101.5%-6.2%16.6%

Return vs Industry: PHM exceeded the Spanish Biotechs industry which returned -6.2% over the past year.

Return vs Market: PHM exceeded the Spanish Market which returned 16.6% over the past year.

Price Volatility

Is PHM's price volatile compared to industry and market?
PHM volatility
PHM Average Weekly Movement10.0%
Biotechs Industry Average Movement7.9%
Market Average Movement2.9%
10% most volatile stocks in ES Market5.4%
10% least volatile stocks in ES Market0.6%

Stable Share Price: PHM's share price has been volatile over the past 3 months compared to the Spanish market.

Volatility Over Time: PHM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Spanish stocks.

About the Company

FoundedEmployeesCEOWebsite
1986509Jose Fernandez Sousa-Farowww.pharmamar.com

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer.

Pharma Mar, S.A. Fundamentals Summary

How do Pharma Mar's earnings and revenue compare to its market cap?
PHM fundamental statistics
Market cap€1.31b
Earnings (TTM)€622.00k
Revenue (TTM)€167.00m

2,102x

P/E Ratio

7.8x

P/S Ratio

Is PHM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHM income statement (TTM)
Revenue€167.00m
Cost of Revenue€9.32m
Gross Profit€157.68m
Other Expenses€157.06m
Earnings€622.00k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.035
Gross Margin94.42%
Net Profit Margin0.37%
Debt/Equity Ratio27.9%

How did PHM perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

1,833%

Payout Ratio